Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a primary emphasis on severe genetic skin disorders and related conditions. The QNRX news feed on Stock Titan aggregates company press releases and market-moving updates that shed light on the progress of its clinical pipeline, regulatory interactions and financing activities.
Investors following QNRX news can see detailed updates on the development of the company’s lead asset, QRX003, a topical lotion in late-stage pivotal trials for Netherton Syndrome. Quoin regularly reports clinical data from investigator-led pediatric studies and pivotal programs, describing changes in skin condition, pruritus, sleep disturbance and use of concomitant medications in Netherton Syndrome patients. News items also cover initial positive data in Peeling Skin Syndrome and the potential versatility of QRX003 across multiple rare skin diseases.
Regulatory and designation milestones are another key component of Quoin’s news flow. The company has announced Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for QRX003 in Netherton Syndrome, as well as Rare Pediatric Disease Designation in the United States. These updates provide context on potential market exclusivity and incentives that may affect the long-term outlook for the program.
Quoin’s news also highlights broader corporate developments, including private placement financings with healthcare-focused institutional investors, adoption of equity incentive plans, leadership changes such as the appointment of a new chief financial officer and shareholder meeting outcomes. In addition, the company issues regular communications about its NETHERTON NOW awareness campaign, releasing video episodes that feature patients, advocates and experts discussing the burden of Netherton Syndrome. For readers tracking QNRX, this news stream offers an ongoing view into clinical progress, regulatory events, capital formation and patient advocacy efforts related to Quoin’s rare disease focus.
Quoin Pharmaceuticals has announced a significant agreement with Hong Kong WinHealth Pharma Group to license and distribute its lead product QRX003 for Netherton Syndrome in Greater China.
The agreement will expand access to rare disease treatments in Hong Kong, Macau, and Taiwan, contingent on regulatory approval, and brings Quoin's global partnerships for QRX003 to nearly 60 countries. With QRX003 potentially being the first treatment for this rare condition, clinical trials are expected to commence shortly.
Skinvisible, Inc. (OTCQB:SKVI) has announced that its licensee Quoin Pharmaceuticals (NASDAQ:QNRX) received FDA acceptance for an Investigational New Drug (IND) application for QRX003, a treatment for Netherton Syndrome. This marks the first IND approval using Skinvisible's proprietary Invisicare drug delivery technology. Successful clinical trials could lead to a milestone payment of $5 million and ongoing royalties for Skinvisible. The approval underscores the potential for expanding applications of their technology in treating rare skin disorders.
Quoin Pharmaceuticals has secured exclusive global rights to a product in development for scleroderma through a new agreement with Queensland University of Technology. This deal involves no upfront fees and allows Quoin to fund the pre-clinical program. The VCAM-1:VL-4 interaction targets immune response in scleroderma, a disease with no current cure. Additionally, Quoin received FDA clearance for its lead product, QRX003, targeting Netherton Syndrome, with clinical trials set to begin in Q2 2022. This positions Quoin to potentially deliver groundbreaking treatments for rare diseases.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has received FDA clearance to initiate clinical testing for its investigational product QRX003, aimed at treating Netherton Syndrome, a rare genetic condition with no current approved treatments. QRX003, a topical lotion that uses proprietary delivery technology, seeks to normalize skin shedding and improve skin barrier function. The company plans to begin clinical trials in the first half of 2022, marking a significant milestone for both Quoin and patients suffering from this serious condition.
Quoin Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for its investigational product QRX003, targeting Netherton Syndrome, a rare genetic disorder with no current treatment options. QRX003 is a topical lotion formulated to restore the skin barrier in affected patients. This IND submission represents a significant milestone for the company as it aims to initiate clinical testing in Q2 2022. Quoin's pipeline also includes additional products for rare diseases, highlighting its commitment to addressing unmet medical needs.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has submitted a Scientific Advice Briefing Document to the European Medicines Agency (EMA) for QRX003, aimed at treating Netherton Syndrome, a rare genetic disease with no current cure. This submission is a critical first step towards advancing the treatment into clinical testing and potential commercialization in the EU. The company has integrated previous feedback received from the FDA into this submission, reflecting its commitment to addressing unmet medical needs in rare diseases.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has expanded its partnership with ER-Kim to include six additional countries for the commercialization of QRX003, a treatment for Netherton Syndrome. This new agreement adds Turkey, Georgia, Azerbaijan, Greece, Cyprus, and Malta to the existing fifteen countries covered in the initial agreement. With this expansion, Quoin now has a total of 60 countries under distribution agreements for QRX003, which aims to be the first approved treatment for this rare genetic disorder lacking current therapies.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has secured an exclusive agreement with Neopharm Medical Supplies to commercialize its investigational drug QRX003 in Israel. This marks the sixth distribution partnership for QRX003 since Quoin's NASDAQ debut in October 2021. The agreement aims to address Netherton Syndrome, a rare genetic disorder with no existing treatment. Quoin's CEO, Dr. Michael Myers, emphasized the importance of expanding the distribution network to ensure global access for patients once the product is approved.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has secured an exclusive distribution agreement with ER-Kim to commercialize its investigational treatment QRX003 across 15 Central and Eastern European countries. This marks Quoin's fifth distribution partnership since its public debut in October 2021, expanding its access to Netherton Syndrome patients in crucial regions. With this agreement, Quoin now has partnerships in a total of 53 countries, reaffirming its commitment to providing treatment options for this rare genetic disease.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced a new exclusive Distribution Agreement with OrphanDC for QRX003, aimed at treating Netherton Syndrome, in Brazil, Argentina, and Colombia. This marks the fourth distribution partnership since going public in October 2021. Quoin will supply QRX003 to OrphanDC under a revenue-sharing model. The company has previously secured agreements for other regions, including the Middle East and North Africa, and continues discussions with additional distributors. Netherton Syndrome is a rare genetic disorder with no current cure.